Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: A potential targeted agent in the treatment of PMBL

Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: A potential targeted agent in the treatment of PMBL

10.18632/oncotarget.27691

Saved in:
Bibliographic Details
Main Authors: Chu, Y., Awasthi, A., Lee, S., Edani, D., Yin, C., Hochberg, J., Shah, T., Chung, T.-H., Ayello, J., van de Ven, C., Klein, C., Lee, D., Cairo, M.S.
Other Authors: CANCER SCIENCE INSTITUTE OF SINGAPORE
Format: Article
Published: Impact Journals LLC 2021
Subjects:
Antibody-dependent cellular cytotoxicity
Obinutuzumab
Primary mediastinal large B-cell lymphoma
Rituximab
Survival
Online Access:https://scholarbank.nus.edu.sg/handle/10635/197598
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore

Similar Items

Similar Items